PDK1 and inflammatory bowel disease: Gerriets and coworkers showed that inhibition of PDK1 using dichloroacetate selectively impairs Th17 proliferation and survival, thereby reducing T-cell-mediated inflammation in inflammatory bowel disease (IBD) and experimental autoimmune encephalitis (EAE) disease models [161].